In conclusion, our results indicate that oncolytic adenovirus treatment can dampen the suppressive TIM-3 checkpoint pathway in murine and patient tumor microenvironments through recruitment of new CD8+ TIL, which reflects alleviation of T-cell exhaustion and adaptive immune modulation across tumor types and correlates with improved overall survival. The gene discussed is HAVCR2; the disease is neoplasm.